Business
GeoVax Reports Second Quarter 2025 Financial Results and Provides Business Update
GEO-MVA received favorable European regulatory guidance supporting streamlined development pathway GEO-CM04S1 demonstrates superior robust immune responses in CLL patients; data presented at EHA 2025 Gedeptin(R) highlighted strong safety and effic...
About this update from Geovax Labs, Inc.
[{"type":"image","caption":"","headline":"GeoVax Labs Announces $1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules","size":{"original":{"width":140,"height":140,"url":"https://media.zenfs.com/en/newsmediawire_165/6b870301b9c37c9b2d12fc8f9b2a2ecc"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/CK3y_RQaAtNDQGf8lPQXOQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTIxMDtjZj13ZWJw/https://media.zenfs.com/en/newsmediawire_165/6b870301b9c37c9b2d12fc8f9b2a2ecc","width":140,"height":140}}},{"type":"text","content":"GEO-MVA received favorable European regulatory guidance supporting streamlined development pathway ","length":98,"tagName":"p"},{"type":"text","content":"GEO-CM04S1 demonstrates superior robust immune responses in CLL patients; data presented at EHA 2025","length":100,"tagName":"p"},{"type":"text","content":"Gedeptin(R) highlighted strong safety and efficacy for the treatment of solid tumors; data presented at AACR 2025","length":113,"tagName":"p"},{"type":"text","content":"Company to host conference call today at 4:30 p.m. ET","length":53,"tagName":"p"},{"type":"text","content":"ATLANTA, GA - July 28, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigenic vaccines and immunotherapies for infectious diseases and cancer, today announced financial results for the second quarter ended June 30, 2025, and provided a business update.","length":319,"tagName":"p"},{"type":"text","content":""The second quarter marked a pivotal period for GeoVax, with compelling clinical data and regulatory milestones reinforcing the strength of our pipeline and our focus on accelerating to commercial status," said David Dodd, GeoVax's Chairman and CEO. "The favorable European regulatory guidance for GEO-MVA, robust immune responses demonstrated by GEO-CM04S1 in immunocompromised patients, particularly those with Chronic Lymphocytic Leukemia (CLL), and the continued progress towards initiation of the Gedeptin(R) Phase 2 trial highlight our expanding footprint in oncology and global infectious disease preparedness. These achievements reflect our commitment to advancing innovative, vaccines and immunotherapies that address urgent and underserved medical needs."","length":789,"tagName":"p"},{"type":"text","content":"Clinical Trial Progress and Operational Developments","l...